However, it seems as if slightly less specific dual inhibitors blocking both transcriptional activity and ERK5 kinase function, such as XMD8-92 [31] or inhibitors targeting ERK5 localization, such as the CDK/ERK5 multi kinase inhibitor TG02, which proved useful for the treatment of myeloma [130], might be a better choice. The gene discussed is MAPK7; the disease is plasma cell myeloma.